Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Response to TheTruth1234 - Lots of Fun Ahead
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Apr 16, 2023 9:15pm
79 Views
Post# 35397718

RE:RE:RE:RE:RE:Response to TheTruth1234 - Lots of Fun Ahead

RE:RE:RE:RE:RE:Response to TheTruth1234 - Lots of Fun AheadBioasis has xB3, TT. It's on Rathjen if she loses it and somebody else makes billions from it. Whether xB3 makes it or not has nothing to do with me. Your claimed 6 years of predictions are ridiculous. Every troll made that prediction but couldn't and didn't back it up. 

However, despite not having enough knowledge to back it up, the trolls proved to be right. Bioasis is, today, a spectacular failure. 15 years of nothing. I wish I had had more influence to cause things to be different. But in the end, all I could do was to comment about things. 

Go put the kids to bed, TT.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities